Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment.

[1]  F. Perticone,et al.  Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study , 2020, British journal of clinical pharmacology.

[2]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[3]  C. Ay,et al.  Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation , 2019, Research and practice in thrombosis and haemostasis.

[4]  R. Bauer,et al.  EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  I. Costache,et al.  Anticoagulation in chronic kidney disease: from guidelines to clinical practice , 2019, Clinical cardiology.

[6]  R. Kreutz,et al.  Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. , 2019, International journal of cardiology.

[7]  W. Ageno,et al.  XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. , 2019, Thrombosis research.

[8]  O. Morel,et al.  Assessment of Renal Dysfunction Improves the Simplified Pulmonary Embolism Severity Index (sPESI) for Risk Stratification in Patients with Acute Pulmonary Embolism , 2019, Journal of clinical medicine.

[9]  G. Guyatt,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. , 2018, Blood advances.

[10]  S. Schirmer,et al.  Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. , 2018, Deutsches Arzteblatt international.

[11]  F. Dentali,et al.  Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism , 2017, Research and practice in thrombosis and haemostasis.

[12]  A. Turpie,et al.  Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment , 2017, Therapeutic advances in cardiovascular disease.

[13]  K. Jurk,et al.  Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations , 2017, International journal of nephrology and renovascular disease.

[14]  L. Beenen,et al.  Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. , 2016, The Lancet. Haematology.

[15]  A. Parkhomenko,et al.  Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. , 2016, JAMA cardiology.

[16]  G. Breithardt,et al.  On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF , 2015, Circulation.

[17]  Z. Harel,et al.  Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease , 2015, Current opinion in nephrology and hypertension.

[18]  P. Verhamme,et al.  Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants , 2014, Thrombosis Journal.

[19]  H. Büller,et al.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. , 2014, Blood.

[20]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[21]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[22]  Jonathan Himmelfarb,et al.  Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport , 2013, Kidney international.

[23]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[24]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[25]  H. Büller,et al.  Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy , 2013, Journal of thrombosis and haemostasis : JTH.

[26]  G. Kumar,et al.  Pulmonary embolism in patients with CKD and ESRD. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[27]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[28]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[29]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[30]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[31]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[32]  A. Folsom,et al.  Chronic kidney disease and venous thromboembolism: a prospective study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  M. Kostrubiec,et al.  Assessment of renal dysfunction improves troponin‐based short‐term prognosis in patients with acute symptomatic pulmonary embolism , 2010, Journal of thrombosis and haemostasis : JTH.

[34]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[35]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[36]  F. Klok,et al.  D-dimer testing in patients with suspected pulmonary embolism and impaired renal function. , 2009, The American journal of medicine.

[37]  A. Maestre,et al.  Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. , 2006, The American journal of medicine.

[38]  L. Dember,et al.  Thrombosis in End‐Stage Renal Disease , 2003, Seminars in dialysis.

[39]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[40]  W. Dippold,et al.  Evaluation of Risk Stratification Markers and Models in Acute Pulmonary Embolism: Rationale and Design of the MARS-PE (Mainz Retrospective Study of Pulmonary Embolism) Study Programme. , 2018, Acta medica.

[41]  S. Goldhaber,et al.  Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. , 2017, Thrombosis and haemostasis.

[42]  W. Ageno,et al.  Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. , 2016, The Lancet. Haematology.

[43]  J. Lutz,et al.  Haemostasis in chronic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.